1091 Results
Sort By:
Published on September 28, 2015
Cynvenio Biosystem and ATGen Global are poised to bring ATGen’s NK Vue™ test to the U.S. market, as a result of a collaborative partnership. NK Vue is an ELISA-based blood test that measures Natural Killer (NK) cell activity. NK cells are part of the innate immune system and represent the…
Published on September 23, 2015
Does being able to test for allergies, STDs, or even cancer in minutes from the comfort and privacy of your home sound like science fiction? Well, a newly designed test from researchers at the University of Montreal could make it a reality before the next Star Trek movie comes to…
Published on August 18, 2015
Biogen, the ALS Association, and Columbia University Medical Center (CUMC) agreed to collaborate to better understand the differences and commonalities in the ALS disease process and how genes influence the clinical features of the disease. The project, “Genomic Translation for ALS Clinical care” (GTAC), will involve a combination of next-generation…
Published on July 10, 2015
Researchers at Johns Hopkins Kimmel Cancer Center report that in a genome-sequencing study of pancreatic cancers and blood in 101 patients at least one-third of the patients' tumors have genetic mutations that may someday help guide precision therapy of their disease. Results of blood tests to detect DNA shed from…
Published on May 14, 2015
Human Longevity (HLI) and the Cleveland Clinic agreed to collaborate to sequence and analyze blood samples from Cleveland Clinic's GeneBank study of de-identified patients. The two organizations will apply whole genome, cancer, and microbiome sequencing focusing on a subset of samples with the goal of discovering novel disease genes and…
Published on May 1, 2015
Cell-free DNA from the maternal blood of a pregnant woman can throw clinicians a curve. Such DNA can indicate whether the genome of a developing fetus contains an abnormal number of chromosomes. Or it may simply indicate that the pregnant woman’s genome contains copy number variants (CNVs). If the latter…
Published on February 10, 2015
Roche has acquired Signature Diagnostics for an undisclosed price. The deal is designed to strengthen Roche’s cancer diagnostics effort with Signature’s expertise in both biobanks and next-generation sequencing (NGS) assays, and is the pharma giant’s fifth deal in less than a year focused on molecular diagnostics and data analysis. Signature…
Published on December 2, 2014
Roche is acquiring Ariosa Diagnostics, a San Jose-based molecular diagnostics testing service provider that offers non-invasive prenatal testing (NIPT) through their CLIA laboratory using cell-free DNA (cfDNA) technology. Ariosa’s Harmony Prenatal Test is designed to assess the risk of Down syndrome and other genetic abnormalities by evaluating fetal cfDNA found…
Published on August 1, 2014
The FDA said Thursday it intends to regulate laboratory-developed tests (LDTs) that it deems as “high-risk” along the lines of Class III medical devices, positioning itself against academic medical centers and other developers of the tests, which have opposed efforts at imposing new rules. The agency formally told Congress it…
Published on May 28, 2014
The history of science is replete with instances of multiple discovery—the more or less simultaneous announcement of essentially the same breakthrough by independent researchers. Still, it may still seem uncanny that two separate research groups not only produced a draft map of the human proteome, they also published their results…